EICHORPublic-registry site landscape for NCT06038578, “A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer”, a Gastric Adenocarcinoma study sponsored by Toray Industries, Inc. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06038578 (registry record) |
| Study title | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
| Official title | A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
| Sponsor | Toray Industries, Inc |
| Condition(s) | Gastric Adenocarcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma |
| Phase | PHASE2 |
| Listed sites | 27 |
| Intervention(s) | TRK-950, Ramucirumab, Paclitaxel |
| Site countries | United States, Japan, South Korea |
Patient-friendly overview of this study: eichor.com/study/NCT06038578.
Eichor generates a preliminary site-risk snapshot for NCT06038578 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
